Liquidia Corporation (LQDA)
NASDAQ: LQDA · Pharmaceutical Preparations · Morrisville, NC
Our rating: Positive
Positive reaffirmed at $55.21, moderate conviction, November 11, 2026.
Breaks if: The Positive call breaks if YUTREPIA's implied quarterly revenue run-rate shows two consecutive sequential declines across the next two 10-Q filings — that would signal the launch curve has bent and the 31× sales multiple becomes very hard to defend at any plausible forward revenue estimate. A material adverse patent ruling or label restriction that narrows the addressable population would also invalidate immediately, regardless of where the price sits.
Key figures
| Market value | $4.9B |
|---|---|
| Revenue, last 12 months | $622M |
| Net income, last 12 months | −$94M |
| Free cash flow, last 12 months | $291M |
| Price to earnings | n/a |
| Free cash flow yield | 5.9% |
| Dividend yield | 0.0% |
| Operating margin | −15.6% |
| Return on equity | n/a |
| Beta to the S&P 500 | 1.07 |
| Volatility, annualized | 76.9% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $225M | 314.6% | $-2.64 | $130M |
| June 30, 2026 | $172M | 1842.7% | $0.74 | $69M |
| March 31, 2026 | $133M | 4158.5% | $0.52 | $50M |
| December 31, 2025 | $92M | 3054.6% | $0.17 | $42M |
| September 30, 2025 | $54M | 1121.7% | $-0.04 | −$11M |
| June 30, 2025 | $9M | 141.5% | $-0.49 | −$41M |
| March 31, 2025 | $3M | 5.0% | $-0.45 | −$31M |
| December 31, 2024 | $3M | −35.6% | $-0.46 | −$22M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $2.25B: Claude 1%, Gemini 5%, Mistral 2%
- Diluted earnings per share are at least $0.17: Claude 35%, Gemini 35%, Mistral 40%
- Free cash flow for the quarter is at least $0.04B: Claude 78%, Gemini 95%, Mistral 88%
41 ledger entries and 44 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.